loratadine - Profile

What are the generic sources for loratadine and what is the scope of patent protection?

Loratadine is the generic ingredient in eleven branded drugs marketed by Bayer Healthcare Llc, Aurobindo Pharma, Bionpharma, Catalent Pharma, Marksans Pharma, Onesource Specialty, Sun Pharma Canada, Aurobindo Pharma Ltd, Hetero Labs Ltd Iii, Lannett Co Inc, Perrigo, Pharm Assoc, Ranbaxy Labs Ltd, Taro, Teva, Wockhardt Bio Ag, Perrigo Pharma Intl, Sun Pharm, Fdn Consumer, Actavis Labs Fl Inc, Glaxosmithkline, Instapill, Rubicon Research, Sun Pharm Inds Ltd, Anda Repository, Apotex, Granules, Hetero Labs Ltd V, Mylan, Pharmobedient, Pld Acquisitions Llc, Unique Pharm, Heritage Pharma, and P And L, and is included in fifty-five NDAs. Additional information is available in the individual branded drug profile pages.

Summary for loratadine

US Patents:	0
Tradenames:	11
Applicants:	34
NDAs:	55
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for loratadine

US Patents and Regulatory Information for loratadine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare Llc	CLARITIN	loratadine	CAPSULE;ORAL	021952-001	Jun 16, 2008		OTC	Yes	Yes
Aurobindo Pharma	LORATADINE	loratadine	CAPSULE;ORAL	211900-001	Mar 24, 2023		OTC	No	No
Bionpharma	LORATADINE	loratadine	CAPSULE;ORAL	202538-001	Dec 21, 2018		OTC	No	No
Catalent Pharma	LORATADINE	loratadine	CAPSULE;ORAL	215127-001	Feb 28, 2025		DISCN	No	No

Expired US Patents for loratadine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Healthcare Llc	CLARITIN	loratadine	SYRUP;ORAL	020641-002	Nov 27, 2002	6,132,758

Loratadine: Market Dominance and Patent Landscape Analysis

Last updated: February 19, 2026

Loratadine, a second-generation H1 antihistamine, maintains a significant market presence driven by its efficacy, safety profile, and extensive generic availability. Key patents have expired, leading to robust competition and price erosion, yet brand loyalty and established market channels contribute to ongoing sales. This analysis examines the patent history, current market dynamics, and investment fundamentals for loratadine.

What is the Patent History of Loratadine?

The foundational patent for loratadine was filed by Schering Corporation (now Merck & Co.) in 1970.

• U.S. Patent No. 4,284,458: Titled "Piperidines and Azacycloalkanes," this patent, issued on August 18, 1981, covered the chemical compound loratadine and its use as an antihistamine. The primary claims focused on the novel chemical structure.
• Exclusivity Period: The patent term was 17 years from the issue date. Therefore, U.S. Patent No. 4,284,458 expired on August 18, 1998.
• Regulatory Exclusivities: In addition to patent protection, loratadine benefited from New Drug Application (NDA) exclusivity periods granted by the U.S. Food and Drug Administration (FDA). The NDA for loratadine (Claritin®) was approved in December 1993. This typically grants five years of market exclusivity from the date of approval, during which generic applications cannot be approved. This exclusivity period would have ended in December 1998.
• Pediatric Exclusivity: Schering-Plough (which acquired the rights from Schering Corporation) also secured a six-month pediatric exclusivity extension for loratadine in 1997, extending its market exclusivity to June 1999.
• Generic Entry: Following the expiry of all patent and regulatory exclusivities, generic versions of loratadine began entering the U.S. market in June 1999. This event significantly altered the competitive landscape.
• Evergreening Strategies: While the core compound patents have long expired, pharmaceutical companies often explore secondary patents related to formulations, delivery methods, or specific therapeutic uses to extend market protection. However, for loratadine, these secondary patents have not resulted in sustained market exclusivity against broad generic competition.

How Has the Market Landscape Evolved Post-Patent Expiry?

The expiry of loratadine's primary patents led to a dramatic shift from a monopolistic branded market to a highly competitive generic environment.

• Generic Erosion: Following generic entry in 1999, the average selling price (ASP) for loratadine products experienced a rapid and substantial decline. This is a standard pattern for successful drugs once patent protection ceases.
• Market Share Domination: Despite price reductions, loratadine has maintained a dominant position in the over-the-counter (OTC) antihistamine market due to its established safety profile and perceived efficacy. It is frequently recommended by healthcare professionals.
• Key Competitors (Branded and Generic):
  • Branded: Claritin® (Merck & Co.) remains a significant player, leveraging brand recognition and marketing efforts. Other branded variations may exist with slightly different formulations or marketing strategies.
  • Generic Manufacturers: A multitude of generic manufacturers produce and market loratadine. Prominent examples include Teva Pharmaceuticals, Mylan (now Viatris), Sandoz, and Aurobindo Pharma. The availability of loratadine from numerous suppliers intensifies price competition.
• Formulations and Product Variations: While the active pharmaceutical ingredient (API) is the same, manufacturers differentiate products through dosage forms (tablets, liquid gels, chewables), strengths (e.g., 10mg), and combination products (e.g., loratadine with pseudoephedrine or dextromethorphan).
• Retailer Private Labels: Major pharmacy chains and retailers (e.g., CVS, Walgreens, Walmart) offer their own private-label versions of loratadine, which are typically priced aggressively and capture a substantial portion of the market share.
• Therapeutic Class Competition: Loratadine competes directly with other second-generation antihistamines like cetirizine (Zyrtec®) and fexofenadine (Allegra®), as well as first-generation antihistamines (though these are less favored due to sedative side effects). The comparative efficacy, side effect profiles, and pricing of these alternatives influence consumer choice and prescription patterns.

What are the Current Sales and Revenue Trends?

Accurate, real-time sales and revenue data for individual generic drugs like loratadine are proprietary and vary significantly between manufacturers and markets. However, general market trends can be inferred.

• Volume-Driven Market: The market for loratadine is now largely volume-driven. While the ASP per unit is low, the sheer quantity of units sold globally generates substantial aggregate revenue.
• Estimated Market Size: The global antihistamines market, of which loratadine is a significant component, is valued in the billions of dollars annually. While precise figures for loratadine alone are difficult to isolate due to its generic nature and inclusion in broader market reports, its market share suggests tens to hundreds of millions of dollars in annual revenue across all manufacturers in key markets like the U.S. and Europe.
• Growth Drivers:
  • Allergy Seasonality: Sales are influenced by seasonal allergy patterns.
  • Increasing Allergy Prevalence: Rising rates of allergic rhinitis globally contribute to sustained demand.
  • OTC Accessibility: Its availability without a prescription facilitates widespread consumer use.
  • Cost-Effectiveness: As a generic medication, it is a cost-effective treatment option for consumers and healthcare systems.
• Challenges to Growth:
  • Price Compression: Intense competition among generic manufacturers and private labels limits pricing power and margin growth.
  • Maturity of the Market: Loratadine is a mature product with a well-established user base. Significant new growth is unlikely without novel formulations or significant shifts in treatment paradigms.
  • Emergence of Newer Therapies: While loratadine remains effective, newer oral and nasal therapies with different mechanisms of action or improved symptom control are available, potentially capturing market share from older generics.

What are the Manufacturing and Supply Chain Considerations?

The manufacturing of loratadine is a mature process, dominated by a global supply chain with a focus on cost efficiency.

• Active Pharmaceutical Ingredient (API) Production: The API for loratadine is manufactured by numerous chemical companies, primarily located in India and China, which are major global hubs for API production due to lower manufacturing costs and established expertise.
• Formulation and Packaging: Finished dosage forms are produced by contract manufacturing organizations (CMOs) and the pharmaceutical companies themselves, also often utilizing facilities in Asia, Europe, and North America.
• Regulatory Compliance: All manufacturing facilities and processes must adhere to strict Good Manufacturing Practices (GMP) regulations set by bodies like the FDA, EMA (European Medicines Agency), and other national health authorities.
• Quality Control: Rigorous quality control measures are implemented throughout the production process, from raw material sourcing to the final packaged product, to ensure safety, efficacy, and purity.
• Supply Chain Risks:
  • Geopolitical Instability: Disruptions in major API-producing regions due to political events or trade disputes can impact supply.
  • Raw Material Costs: Fluctuations in the cost of key precursor chemicals can affect manufacturing expenses.
  • Logistics and Shipping: Global shipping delays or increased freight costs can affect product availability and cost.
  • Regulatory Changes: New or updated regulatory requirements can necessitate process modifications and incur costs.
• Brand vs. Generic Manufacturing: Branded manufacturers like Merck may maintain higher-margin, vertically integrated supply chains or partner with select CMOs. Generic manufacturers typically focus on securing the lowest cost API and most efficient formulation and packaging to compete on price.

What are the Investment Fundamentals for Loratadine?

Investing in loratadine as a standalone product presents specific opportunities and risks, largely centered around its status as a mature, genericized commodity.

• Investment Thesis - Generic Manufacturers/API Suppliers:
  • Volume Play: Investment would focus on companies with significant scale in generic API production or finished dosage form manufacturing. Revenue generation is driven by high-volume sales.
  • Cost Leadership: Companies that can achieve and maintain the lowest cost of production will have a competitive advantage.
  • Diversification: Loratadine is likely a single product within a much larger portfolio for most manufacturers. Investment should consider the company's overall product pipeline and market position.
  • Predictable Demand: Allergy medications have consistent, albeit seasonal, demand, providing a degree of revenue stability.
• Investment Thesis - Branded Manufacturer (e.g., Merck & Co.):
  • Brand Loyalty & Marketing: Merck leverages brand equity and extensive marketing to maintain a premium price for Claritin® over generics, albeit a reduced premium compared to its pre-generic era.
  • Portfolio Contribution: Claritin® contributes to Merck's broader consumer health or allergy division, not typically a primary driver of overall company valuation, but a steady revenue stream.
  • Diversification Benefits: Investment in Merck would be for its diversified pharmaceutical portfolio, not solely loratadine.
• Risks:
  • Margin Compression: The primary risk is the ongoing pressure on profit margins due to intense competition.
  • Lack of Innovation: As a mature product, there is limited opportunity for significant revenue growth through innovation.
  • Regulatory Scrutiny: Generic drug pricing and manufacturing practices can face regulatory and public scrutiny.
  • Therapeutic Obsolescence: While unlikely in the short to medium term, the emergence of significantly superior or more convenient allergy treatments could erode loratadine's market share.
• Valuation Considerations:
  • Price/Earnings (P/E) Ratios: Companies heavily reliant on mature generics may trade at lower P/E multiples compared to companies with strong pipelines of novel drugs.
  • Revenue Stability: The stable demand for loratadine can support a stable revenue stream, contributing to a company's overall financial predictability.
  • Market Share and Market Penetration: Companies with significant market share in loratadine production are likely to benefit from consistent sales volume.

What are the Regulatory and Compliance Requirements?

Loratadine, as a widely used pharmaceutical, is subject to stringent regulatory oversight across its lifecycle.

• Drug Approval Process: Generic versions of loratadine require Abbreviated New Drug Applications (ANDAs) to be approved by regulatory agencies such as the U.S. FDA. The ANDA process demonstrates bioequivalence to the reference listed drug (Claritin®).
• Good Manufacturing Practices (GMP): All manufacturing facilities producing loratadine API or finished products must comply with current GMP regulations to ensure product quality, safety, and consistency. This includes rigorous process validation, quality control testing, and documentation.
• Labeling and Advertising: Claims made on product labeling and in advertising must be accurate, substantiated, and compliant with regulatory guidelines. For OTC products, this includes clear instructions for use, warnings, and indications.
• Post-Market Surveillance: Manufacturers are required to monitor and report adverse events associated with their products to regulatory authorities. This pharmacovigilance activity helps identify potential safety issues.
• Environmental Regulations: The manufacturing process, particularly API synthesis, must adhere to environmental regulations concerning waste disposal and emissions.
• Intellectual Property Enforcement: While primary patents have expired, any secondary patents related to formulations or processes are subject to potential litigation and enforcement actions.
• International Regulations: Manufacturers exporting loratadine must comply with the specific regulations of each importing country, which may differ from U.S. FDA requirements.

Key Takeaways

• Patent Expiry Impact: Loratadine's market was fundamentally reshaped by the expiration of its core patents in the late 1990s, leading to widespread genericization.
• Market Dominance in Generics: Despite intense price competition, loratadine remains a leading OTC antihistamine due to its established safety and efficacy.
• Volume-Driven Revenue: The current market is characterized by high sales volume rather than high profit margins per unit.
• Globalized Supply Chain: API production is concentrated in regions like India and China, with finished product manufacturing occurring globally.
• Investment Focus: Investment opportunities lie primarily with large-scale generic manufacturers and API suppliers focused on cost efficiency, or with diversified pharmaceutical companies that include loratadine in their portfolios.
• Strict Regulatory Oversight: Loratadine is subject to comprehensive regulatory compliance, from manufacturing to marketing.

Frequently Asked Questions

1. What is the current patent status of loratadine? The primary patents covering the compound loratadine and its initial uses have long expired. Any existing patents are likely related to specific formulations, delivery systems, or manufacturing processes, which may offer limited protection against generic competition.

2. How does loratadine compare in efficacy and safety to other OTC antihistamines? Loratadine is a second-generation antihistamine known for its non-sedating properties compared to first-generation agents. It is generally considered to have a favorable safety profile and comparable efficacy to other second-generation antihistamines like cetirizine and fexofenadine, with individual patient responses varying.

3. What is the typical pricing strategy for loratadine products in the current market? Pricing is highly competitive, driven by generic manufacturers and retailer private labels. Prices vary based on quantity, formulation, and brand (branded vs. generic), with generic options offering the lowest cost per dose.

4. Are there any significant unmet needs or future opportunities related to loratadine? Given its maturity, significant new market opportunities for loratadine itself are limited. Opportunities may arise from novel combination products or improved delivery systems, but these would require substantial R&D and regulatory approval.

5. What are the main risks for companies manufacturing or marketing loratadine? The primary risks include intense price competition leading to margin erosion, supply chain disruptions, potential regulatory changes, and the possibility of newer, more effective allergy treatments gaining market dominance.

Citations

[1] United States Patent 4,284,458. (1981). Piperidines and azacycloalkanes. Retrieved from USPTO database. [2] U.S. Food and Drug Administration. (n.d.). Orphan Drug Act and Pediatric Exclusivity. Retrieved from FDA website. [3] Various Pharmaceutical Industry Market Research Reports (e.g., Global Antihistamines Market, Generic Pharmaceuticals Market) published by firms such as Grand View Research, MarketsandMarkets, and Mordor Intelligence. (Specific report titles and publication dates vary and are proprietary). [4] U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Application (ANDA) Program. Retrieved from FDA website. [5] World Health Organization. (n.d.). Good Manufacturing Practices (GMP). Retrieved from WHO website.